Sources Wegovy 7.2mg Solution for Injection in Pre-Filled Pen Summary of Product Characteristics, Electronic Medicines Compendium: medicines.org.uk/emc/product/102093/smpc Wegovy 2.4mg FlexTouch Summary of Product Characteristics, Electronic Medicines Compendium: medicines.org.uk/emc/product/13803/smpc MHRA approval of the single-dose 7.2mg injection device, Novo Nordisk press release via PharmiWeb (14 April 2026): pharmiweb.com "'Triple-strength' Wegovy injection gets MHRA approval," Pharmacy Magazine: pharmacymagazine.co.uk Wegovy (semaglutide) EPAR Product Information, European Medicines Agency: ema.europa.eu STEP UP trial (NCT05646706), Once-weekly semaglutide 7.2mg in adults with obesity The Lancet Diabetes & Endocrinology: thelancet.com "STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity" (treatment policy estimand results), HCPLive: hcplive.com "Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial" (trial product estimand results), HCPLive: hcplive.com "STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs

The peptides influence on over 4,000 human genes means its effects extend well beyond the dermis
Survodutide (BI 456906) was evaluated in two phase I studies involving healthy volunteers and individuals with overweight/obesity
That's not a reason to assume it won't do anything for you
Methods: A retrospective chart review was conducted, and 58 adults with epilepsy undergoing MAD were evaluated